An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR+/HER2- MBC, including the optimal application of CDK4/6 inhibitors, the evolving role of PI3K pathway blockade, promising strategies on the horizon for managing resistance, and panel case discussions.
Joyce O'Shaughnessy, MD
Program Director
Adam M. Brufsky, MD, PhD
Sara Hurvitz, MD, FACP
Released: July 5, 2019 Expiration: No longer available for credit

Related Content

In this downloadable slideset from Clinical Care Options (CCO) Nadia Harbeck, MD, PhD examines the evidence on checkpoint inhibitor therapy in TNBC.

person default Nadia Harbeck, MD, PhD Released: May 11, 2021

In this downloadable slideset from Clinical Care Options (CCO) Ian Krop, MD, PhD explores the evolving role of antibody-drug conjugates in TNBC.

Ian E. Krop, MD, PhD Released: May 11, 2021

Prof. Dr. Arndt Hartmann Released: April 9, 2021

Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer in a webcast presented by Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.